Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av farmasøytintervensjon for personer med ukontrollert type 2-diabetes

16. september 2026 oppdatert av: University of Manitoba

Evaluering av farmasøytintervensjon og utdanning i en pasientsentrert, tverrfaglig tilnærming for personer med ukontrollert type 2-diabetes

Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.

Studieoversikt

Detaljert beskrivelse

Recruitment will begin in July 2022, potential participants can self-refer or another healthcare provider may discuss the study and provide contact information to the study team for all interested potential participants. These potential participants would then be screened for eligibility by the pharmacist or PharmD (Doctor of Pharmacy) Intern. The goal is to enroll 60 participants in the study. All participants must provide consent to participate and will be asked to complete a participant survey.

All participants who consented will then be randomized into a control group which will not receive pharmacist intervention during the study period, or the intervention group which will receive pharmacist/PharmD Intern led intervention which includes a medication review, optimizing medication treatment options and frequent follow up and diabetes education. The control group participants will be offered pharmacist intervention following the study period. All participants will be asked to complete a participant survey at the start and end of the study. All participants will also have standard care from their physicians and other healthcare team members as required which would be standard of practice. All participants would also be asked to repeat their blood work at the end of the study period.

Studietype

Intervensjonell

Registrering (Faktiske)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Manitoba
      • Portage la Prairie, Manitoba, Canada, R1N 3V5
        • Portage Clinic

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients whose primary care physician is within the Portage Clinic
  • Adults (age 18 and older) with type 2 diabetes with HbA1C 10 % or above
  • Patients whom have not had previous clinical pharmacist directed intervention
  • Agree to participate in the study, including frequent follow up, blood glucose home monitoring as directed and repeat lab work
  • Willing to consider medication adjustments as deemed appropriate
  • Willing to review and sign the Research Participant Information and Informed Consent Form

Exclusion Criteria:

  • Patients less than 18 years of age
  • Patients with type 1 diabetes, pre-diabetes or gestational diabetes (or whom are pregnant)
  • Patients whom have had recent or ongoing clinical pharmacist directed intervention or intensive health care professional monitoring and guidance
  • Patients with HbA1C less than 10%
  • Patients whom refuse medication adjustments
  • Patients with severe renal impairment or receiving dialysis treatments

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Control Arm

The participants in this arm will receive standard of care from their physician as they would have been doing previously. This still may involve blood work, referrals to other health providers (except pharmacist) and medication adjustments driven by the pharmacist.

Aktiv komparator: Pharmacist Intervention Arm

The participants in this arm will receive standard of care from their physician in addition to pharmacist intervention. The pharmacist or pharmD intern leads the diabetes care for the patient typically, conducting a medication review, recommending medication changes, frequent follow up and requesting blood work and providing referrals to other health care providers as needed,which is standard care

Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Baseline Hemoglobin A1C (HbA1C) at 10 months
Tidsramme: baseline and through study completion at 10 months approximately

Measure of blood glucose control at the lab

baseline and through study completion at 10 months approximately

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participant Survey
Tidsramme: baseline and through study completion at 10 months approximately

Evaluating the patients knowledge of diabetes management, comfort with managing their own diabetes care, perception of the pharmacist's role

baseline and through study completion at 10 months approximately
Modifiable Risk Factors -Cholesterol Level
Tidsramme: baseline and through study completion at 10 months approximately

evaluating changes in modifiable risk factors such as cholesterol levels reported in mmol/L

baseline and through study completion at 10 months approximately
Modifiable Risk Factor - Body Mass Index
Tidsramme: baseline and through study completion at 10 months approximately

evaluating changes in modifiable risk factors such as weight and height which will be combined to report body mass index in kg/m^2

baseline and through study completion at 10 months approximately
Modifiable Risk Factor - Blood Pressure
Tidsramme: baseline and through study completion at 10 months approximately

evaluating changes in modifiable risk factors such as blood pressure reported in mmHg

baseline and through study completion at 10 months approximately

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. juli 2022

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

20. juni 2022

Først innsendt som oppfylte QC-kriteriene

28. juni 2022

Først lagt ut (Faktiske)

5. juli 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere